ANGPTL2 renders colorectal cancer cells resistant to chemotherapy by activating Syk-PI3K-dependent anti-apoptotic signaling
===========================================================================================================================

**Page 1550--9**

Inflammatory mediators are extensively involved in cancer development and many investigations are under way to elaborate upon their role in various malignancies. In previous work, Horiguchi and colleagues discovered the importance of angiopoietin-like protein 2 (ANGPTL2) in promoting tumorigenesis. Here, the authors extend the understanding of ANGPTL2 by probing its role in colorectal cancer (CRC), one of the most common and deadly malignancies worldwide. Multimodality therapy is often used in treating CRC and the chemotherapeutic drug 5-FU is a mainstay of treatment. In the exciting work presented in this issue, the authors support their hypothesis that ANGPTL2 is an anti-carcinostatic inflammatory mediator. They demonstrate that overexpression of ANGPTL2 is associated with a reduced efficacy of 5-FU and with an upregulation of antiapoptotic cell signaling molecules, such as BCL-2 and BCL-XL. Their findings expand our understanding of this important immune modulator in the role of CRC and potentially many other cancers.
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Silencing of STRN4 suppresses the malignant characteristics of cancer cells
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The striatin protein family consists of a variety of proteins that form large complexes with other phosphatases and kinases. Individual striatin proteins are expressed in a wide variety of normal tissues throughout the body and are active during stages of development. There is a known role for straitins in cell propagation and apoptosis, which has implicated these as potential cancer markers. Peripheral evidence has implicated one striatin, STRN4, in tumor development. Here, Wong and others probe the potential role of STRN4 in carcinogenesis using an *in vitro* cell culture assay as well as *in vivo* mice experiments. In one experiment in their extensive study, the authors use an STRN4 knockdown mouse strain to demonstrate the increased sensitivity of pancreatic cancer cells to chemotherapy. This study illustrates the importance of the striatin protein family in cancer development, and specifically implicates STRN4 in this novel role.
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Antitumor effects of tyropeptin--boronic acid derivatives: New proteasome inhibitors
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The proteasome is responsible for degrading biologic components of cells, including many modulators of the cell cycle and cellular proliferation. It is thought that aberrant division in some cells may be secondary to inappropriate degradation of tumor suppressors or regulators of the cell cycle. Accordingly, these processes may lead to unchecked cell division and may promote cancer propagation. Here, Momose *et al*. present their description of two novel proteasome inhibitors that lead to increased apoptosis and tumor suppression in a mouse model of multiple myeloma. Other proteasome inhibitors have been developed to treat multiple myeloma and there is a need for additional drugs to more effectively treat this often terminal disease. The authors' findings suggest that proteasome inhibition with these new agents may serve as an alternative therapeutic strategy in human myeloma patients.
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